Role of Gut Microbial Metabolites in Cardiovascular Diseases—Current Insights and the Road Ahead
dc.contributor.author | Datta, Sayantap | |
dc.contributor.author | Pasham, Sindhura | |
dc.contributor.author | Inavolu, Sriram | |
dc.contributor.author | Boini, Krishna M. | |
dc.contributor.author | Koka, Saisudha | |
dc.date.accessioned | 2024-09-27T13:19:17Z | |
dc.date.available | 2024-09-27T13:19:17Z | |
dc.date.issued | 2024-09-23 | |
dc.date.updated | 2024-09-27T13:19:17Z | |
dc.description.abstract | Cardiovascular diseases (CVDs) are the leading cause of premature morbidity and mortality globally. The identification of novel risk factors contributing to CVD onset and progression has enabled an improved understanding of CVD pathophysiology. In addition to the conventional risk factors like high blood pressure, diabetes, obesity and smoking, the role of gut microbiome and intestinal microbe-derived metabolites in maintaining cardiovascular health has gained recent attention in the field of CVD pathophysiology. The human gastrointestinal tract caters to a highly diverse spectrum of microbes recognized as the gut microbiota, which are central to several physiologically significant cascades such as metabolism, nutrient absorption, and energy balance. The manipulation of the gut microbial subtleties potentially contributes to CVD, inflammation, neurodegeneration, obesity, and diabetic onset. The existing paradigm of studies suggests that the disruption of the gut microbial dynamics contributes towards CVD incidence. However, the exact mechanistic understanding of such a correlation from a signaling perspective remains elusive. This review has focused upon an in-depth characterization of gut microbial metabolites and their role in varied pathophysiological conditions, and highlights the potential molecular and signaling mechanisms governing the gut microbial metabolites in CVDs. In addition, it summarizes the existing courses of therapy in modulating the gut microbiome and its metabolites, limitations and scientific gaps in our current understanding, as well as future directions of studies involving the modulation of the gut microbiome and its metabolites, which can be undertaken to develop CVD-associated treatment options. Clarity in the understanding of the molecular interaction(s) and associations governing the gut microbiome and CVD shall potentially enable the development of novel druggable targets to ameliorate CVD in the years to come. | |
dc.identifier | doi: 10.3390/ijms251810208 | |
dc.identifier.citation | International Journal of Molecular Sciences 25 (18): 10208 (2024) | |
dc.identifier.uri | https://hdl.handle.net/10657/18128 | |
dc.title | Role of Gut Microbial Metabolites in Cardiovascular Diseases—Current Insights and the Road Ahead |